Marc Ladanyi Selected Research

Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)

1/2022	Precision medicine in non-small cell lung cancer: Current applications and future directions.
1/2022	MYC Promotes Tyrosine Kinase Inhibitor Resistance in ROS1-Fusion-Positive Lung Cancer.
1/2022	Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements.
1/2021	Response to Standard Therapies and Comprehensive Genomic Analysis for Patients with Lung Adenocarcinoma with EGFR Exon 20 Insertions.
1/2019	Exceptional responders with invasive mucinous adenocarcinomas: a phase 2 trial of bortezomib in patients with KRAS G12D-mutant lung cancers.
1/2019	Activation of KRAS Mediates Resistance to Targeted Therapy in MET Exon 14-mutant Non-small Cell Lung Cancer.
1/2018	RASA1 and NF1 are Preferentially Co-Mutated and Define A Distinct Genetic Subset of Smoking-Associated Non-Small Cell Lung Carcinomas Sensitive to MEK Inhibition.
1/2018	Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing.
12/2016	Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial.
3/2016	JAK2 inhibition sensitizes resistant EGFR-mutant lung adenocarcinoma to tyrosine kinase inhibitors.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Marc Ladanyi Research Topics

Disease

252	Neoplasms (Cancer) 05/2022 - 01/2002
72	Lung Neoplasms (Lung Cancer) 01/2022 - 08/2005
56	Adenocarcinoma of Lung 01/2021 - 01/2005
37	Sarcoma (Soft Tissue Sarcoma) 01/2022 - 07/2002
21	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2022 - 02/2006
18	Adenocarcinoma 01/2020 - 01/2005
15	Carcinogenesis 01/2022 - 01/2003
13	Carcinoma (Carcinomatosis) 01/2021 - 08/2003
13	Synovial Sarcoma (Synovioma) 12/2018 - 02/2002
12	Renal Cell Carcinoma (Grawitz Tumor) 01/2022 - 06/2003
11	Breast Neoplasms (Breast Cancer) 01/2022 - 08/2003
10	Colorectal Neoplasms (Colorectal Cancer) 01/2019 - 07/2010
9	Neoplasm Metastasis (Metastasis) 10/2020 - 04/2008
9	Mesothelioma 01/2020 - 06/2003
9	Ewing Sarcoma (Sarcoma, Ewing) 02/2016 - 07/2002
8	Malignant Mesothelioma 01/2021 - 02/2010
7	Rhabdomyosarcoma 01/2022 - 10/2004
7	Microsatellite Instability 01/2021 - 01/2017
6	Genetic Translocation (Chromosomal Translocation) 04/2022 - 11/2002
6	Disease Progression 01/2021 - 02/2006
6	Osteosarcoma (Osteogenic Sarcoma) 11/2019 - 08/2004
4	Prostatic Neoplasms (Prostate Cancer) 01/2022 - 11/2011
4	Leiomyosarcoma 01/2021 - 01/2018
4	Thyroid Neoplasms (Thyroid Cancer) 01/2021 - 06/2009
4	Alveolar Soft Part Sarcoma 10/2011 - 06/2003
3	Desmoplastic Small Round Cell Tumor 04/2022 - 01/2021
3	Chondrosarcoma 01/2020 - 01/2003
3	Brain Neoplasms (Brain Tumor) 01/2020 - 06/2015
3	Melanoma (Melanoma, Malignant) 01/2019 - 07/2012
3	Astrocytoma (Pilocytic Astrocytoma) 01/2019 - 02/2005
3	Glioma (Gliomas) 01/2019 - 10/2010
3	Glioblastoma (Glioblastoma Multiforme) 12/2018 - 06/2009
3	Leukemia 01/2018 - 06/2003
3	Gastrointestinal Stromal Tumors (Gastrointestinal Stromal Tumor) 07/2012 - 06/2003

Drug/Important Bio-Agent (IBA)

47	ErbB Receptors (EGF Receptor)IBA 01/2021 - 01/2005
44	Proteins (Proteins, Gene)FDA Link 01/2022 - 05/2002
44	DNA (Deoxyribonucleic Acid)IBA 01/2022 - 09/2004
42	Tyrosine Kinase InhibitorsIBA 01/2022 - 11/2006
41	Phosphotransferases (Kinase)IBA 04/2022 - 01/2005
27	Biomarkers (Surrogate Marker)IBA 01/2022 - 08/2003
25	Erlotinib Hydrochloride (CP 358,774)FDA Link 01/2020 - 01/2005
24	Biological ProductsIBA 01/2022 - 01/2002
22	Transcription Factors (Transcription Factor)IBA 04/2022 - 07/2002
19	Gefitinib (Iressa)FDA Link 02/2015 - 01/2005
16	RNA (Ribonucleic Acid)IBA 01/2021 - 09/2004
14	ParaffinIBA 01/2022 - 06/2003
13	Immune Checkpoint InhibitorsIBA 01/2022 - 01/2017
13	Messenger RNA (mRNA)IBA 01/2021 - 08/2002
13	Pharmaceutical PreparationsIBA 01/2021 - 12/2007
12	Formaldehyde (Formol)FDA Link 01/2022 - 06/2003
12	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 12/2015 - 06/2003
11	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2021 - 11/2008
10	Cell-Free Nucleic AcidsIBA 01/2022 - 01/2017
9	CrizotinibIBA 01/2021 - 10/2010
9	Anaplastic Lymphoma KinaseIBA 01/2019 - 02/2012
8	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2022 - 08/2005
7	AfatinibIBA 01/2022 - 10/2012
5	Estrogen ReceptorsIBA 01/2022 - 09/2011
5	Cathepsin KIBA 01/2022 - 09/2010
5	AntigensIBA 11/2021 - 02/2002
5	ChromatinIBA 01/2021 - 01/2012
5	cabozantinibIBA 12/2020 - 06/2013
5	tyrosine receptor (receptor, tyrosine)IBA 12/2019 - 11/2008
5	Oncogene Proteins (Oncogene Protein)IBA 12/2018 - 04/2013
5	Monoclonal AntibodiesIBA 08/2014 - 02/2002
4	selpercatinibIBA 01/2022 - 12/2019
4	human ERBB2 proteinIBA 03/2021 - 02/2012
4	DesminIBA 01/2021 - 08/2013
4	larotrectinibIBA 01/2020 - 01/2018
4	osimertinibIBA 01/2020 - 01/2017
4	Imatinib Mesylate (Gleevec)FDA Link 03/2015 - 06/2003
4	AntibodiesIBA 09/2013 - 08/2005
4	Keratins (Keratin)IBA 09/2010 - 08/2002
4	SYT-SSX fusion proteinIBA 07/2006 - 01/2002
3	Telomerase (Telomerase Reverse Transcriptase)IBA 05/2022 - 04/2003
3	NucleotidesIBA 01/2022 - 07/2017
3	MART-1 AntigenIBA 01/2022 - 11/2019
3	LigandsIBA 01/2021 - 07/2012
3	Cyclin D1IBA 01/2021 - 12/2007
3	Poly(ADP-ribose) Polymerase InhibitorsIBA 01/2021 - 01/2019
3	Sirolimus (Rapamycin)FDA Link 01/2021 - 05/2011
3	Mitogen-Activated Protein KinasesIBA 10/2018 - 11/2008
3	AsbestosIBA 07/2017 - 09/2004
3	MicroRNAs (MicroRNA)IBA 10/2016 - 08/2009
3	Small Interfering RNA (siRNA)IBA 01/2016 - 08/2010
3	Codon (Codons)IBA 03/2015 - 09/2008
3	Insulin-Like PeptidesIBA 09/2014 - 03/2003
3	EWS-FLI fusion proteinIBA 01/2012 - 07/2002
3	Mucin-1 (CA 15-3 Antigen)IBA 09/2010 - 08/2002
3	Threonine (L-Threonine)FDA Link 11/2008 - 11/2006
3	Methionine (L-Methionine)FDA Link 12/2007 - 06/2003
3	RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA 03/2006 - 02/2002
3	EnzymesIBA 07/2005 - 06/2003
2	Hormones (Hormone)IBA 01/2022 - 10/2018
2	Cetuximab (Erbitux)FDA Link 01/2022 - 06/2015

Therapy/Procedure

109	Therapeutics 01/2022 - 06/2003
18	Drug Therapy (Chemotherapy) 01/2022 - 12/2003
17	Immunotherapy 01/2022 - 02/2002
4	Precision Medicine 01/2022 - 12/2015
4	Aftercare (After-Treatment) 01/2021 - 03/2008